Literature DB >> 16710078

Difference of progression to AIDS according to CD4 cell count, plasma HIV RNA level and the use of antiretroviral therapy among HIV patients infected through blood products in japan.

Miyuki Kawado1, Shuji Hashimoto, Takuhiro Yamaguchi, Shin-ichi Oka, Kazuyuki Yoshizaki, Satoshi Kimura, Katsuyuki Fukutake, Satoshi Higasa, Takuma Shirasaka.   

Abstract

BACKGROUND: It is important to examine progression to acquired immunodeficiency syndrome (AIDS) or death and its predictors among human immunodeficiency virus (HIV) infected persons before and after the introduction of the highly active antiretroviral therapy (HAART) available in Japan since 1997.
METHODS: The data used were from a survey of persons with HIV infected through blood coagulation factor products in Japan. Progression to AIDS or death during two periods, between January 1994 and March 1997, and between April 1997 and March 2002, were observed.
RESULTS: The AIDS-free proportion after 3 years was 74% among 417 participants for the earlier period and 94% among 605 participants in the later one. The hazard ratio of low CD4 cell count (less than 200 cells/microL) was 50.8 for the earlier period and 4.7 for the later one compared with that of 500 cells/microL or more. After adjustment by plasma HIV RNA levels and use of antiretroviral therapy, the hazard ratios of the low CD4 cell count for the later period were still significant.
CONCLUSION: The AIDS-free proportion among people with HIV infected through blood products in Japan largely increased after the introduction of HAART. The CD4 cell count remains an important predictor of future progression, but its importance might be less because of HAART.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710078     DOI: 10.2188/jea.16.101

Source DB:  PubMed          Journal:  J Epidemiol        ISSN: 0917-5040            Impact factor:   3.211


  5 in total

Review 1.  Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up.

Authors:  Shinichi Oka; Kazuko Ikeda; Misao Takano; Miwa Ogane; Junko Tanuma; Kunihisa Tsukada; Hiroyuki Gatanaga
Journal:  Glob Health Med       Date:  2020-02-29

2.  Clinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood Products.

Authors:  Miyuki Kawado; Shuji Hashimoto; Shin-Ichi Oka; Katsuyuki Fukutake; Satoshi Higasa; Hiroshi Yatsuhashi; Miwa Ogane; Manabu Okamoto; Takuma Shirasaka
Journal:  Open AIDS J       Date:  2017-04-26

3.  Rates and risk factors associated with the progression of HIV to AIDS among HIV patients from Zhejiang, China between 2008 and 2012.

Authors:  Lin Chen; Jiezhe Yang; Renjie Zhang; Yun Xu; Jinlei Zheng; Jianmin Jiang; Jun Jiang; Lin He; Ning Wang; Philip Chun Yeung; Xiaohong Pan
Journal:  AIDS Res Ther       Date:  2015-09-25       Impact factor: 2.250

Review 4.  A Comparative Systematic Review of the Optimal CD4 Cell Count Threshold for HIV Treatment Initiation.

Authors:  Babatunde Olubajo; Kathryn Mitchell-Fearon; Oluseye Ogunmoroti
Journal:  Interdiscip Perspect Infect Dis       Date:  2014-03-20

5.  MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.

Authors:  Saif Ullah Munshi; Harekrushna Panda; Prasida Holla; Bharat Bhushan Rewari; Shahid Jameel
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.